Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction.
Rocca C, De Bartolo A, Grande F, Rizzuti B, Pasqua T, Giordano F, Granieri MC, Occhiuzzi MA, Garofalo A, Amodio N, Cerra MC, Schneider F, Panno ML, Metz-Boutigue MH, Angelone T.
Rocca C, et al. Among authors: metz boutigue mh.
Int Immunopharmacol. 2021 May;94:107487. doi: 10.1016/j.intimp.2021.107487. Epub 2021 Feb 23.
Int Immunopharmacol. 2021.
PMID: 33636560